Research graph
References from Kidney-sparing immunotherapy for lynch syndrome-associated upper tract urothelial carcinoma following colon cancer: a case report. Local targets link to admitted publications; unresolved targets remain external evidence.
Lynch syndrome, molecular mechanisms and variant classification
10.1038/s41416-022-02059-z · 2023 · External reference
Update on lynch syndrome genomics
10.1007/s10689-016-9882-8 · 2016 · External reference
Diagnosis of lynch syndrome and strategies to distinguish lynch-related tumors from sporadic MSI/dMMR tumors
10.3390/cancers13030467 · 2021 · External reference
Lynch syndrome genetics and clinical implications
10.1053/j.gastro.2022.08.058 · 2023 · External reference
Lynch syndrome: its impact on urothelial carcinoma
10.3390/ijms22020531 · 2021 · External reference
Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis
10.1016/j.urolonc.2026.110999 · 2026 · External reference
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis
10.1136/bmjonc-2024-000335 · 2024 · External reference
Detection of urothelial carcinoma in lynch syndrome using microsatellite instability analysis of urine cell-free DNA
10.1016/j.ebiom.2025.105969 · 2025 · External reference
Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer
10.1200/jco.19.01021 · 2019 · External reference
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
10.1016/j.annonc.2022.05.519 · 2022 · External reference
Efficacy of immune checkpoint blockade in advanced upper tract urothelial cancer with DNA mismatch repair deficiency or microsatellite instability
10.1200/po-25-00772 · 2026 · External reference
Hereditary colorectal cancer syndromes: american society of clinical oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: european society for medical oncology clinical practice guidelines
10.1200/jco.2014.58.1322 · 2015 · External reference
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RaNeO) research consortium)
10.1007/s00345-022-04156-3 · 2022 · External reference
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017 · External reference
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
10.1186/s13045-019-0738-1 · 2019 · External reference
Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03
10.1158/1078-0432.ccr-21-2210 · 2022 · External reference
Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial
10.1093/oncolo/oyag050 · 2026 · External reference
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results
10.1200/jco.19.00538 · 2019 · External reference
Case report: neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
10.3389/fonc.2022.985177 · 2022 · External reference
Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline
10.1097/ju.0000000000003480 · 2023 · External reference
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RaNeO) research consortium)
10.1007/s00345-022-04156-3 · ExternalCitation · doi-reference
Update on lynch syndrome genomics
10.1007/s10689-016-9882-8 · ExternalCitation · doi-reference
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
10.1016/j.annonc.2022.05.519 · ExternalCitation · doi-reference
Detection of urothelial carcinoma in lynch syndrome using microsatellite instability analysis of urine cell-free DNA
10.1016/j.ebiom.2025.105969 · ExternalCitation · doi-reference
Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis
10.1016/j.urolonc.2026.110999 · ExternalCitation · doi-reference
Lynch syndrome, molecular mechanisms and variant classification
10.1038/s41416-022-02059-z · ExternalCitation · doi-reference
Lynch syndrome genetics and clinical implications
10.1053/j.gastro.2022.08.058 · ExternalCitation · doi-reference
Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial
10.1093/oncolo/oyag050 · ExternalCitation · doi-reference
Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline
10.1097/ju.0000000000003480 · ExternalCitation · doi-reference
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · ExternalCitation · doi-reference
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis
10.1136/bmjonc-2024-000335 · ExternalCitation · doi-reference
Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03
10.1158/1078-0432.ccr-21-2210 · ExternalCitation · doi-reference
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
10.1186/s13045-019-0738-1 · ExternalCitation · doi-reference
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results
10.1200/jco.19.00538 · ExternalCitation · doi-reference
Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer
10.1200/jco.19.01021 · ExternalCitation · doi-reference
Hereditary colorectal cancer syndromes: american society of clinical oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: european society for medical oncology clinical practice guidelines
10.1200/jco.2014.58.1322 · ExternalCitation · doi-reference
Efficacy of immune checkpoint blockade in advanced upper tract urothelial cancer with DNA mismatch repair deficiency or microsatellite instability
10.1200/po-25-00772 · ExternalCitation · doi-reference
Case report: neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
10.3389/fonc.2022.985177 · ExternalCitation · doi-reference
Diagnosis of lynch syndrome and strategies to distinguish lynch-related tumors from sporadic MSI/dMMR tumors
10.3390/cancers13030467 · ExternalCitation · doi-reference
Lynch syndrome: its impact on urothelial carcinoma
10.3390/ijms22020531 · ExternalCitation · doi-reference
